產(chǎn)品中心Cell Resources
聯(lián)系我們CONTACT US
400-999-210024小時(shí)服務(wù)熱線(xiàn)
[email protected]銷(xiāo)售郵箱
產(chǎn)品概述
| 名稱(chēng) | BHT101 (人甲狀腺癌細(xì)胞(未分化)) (STR鑒定正確) |
| 別稱(chēng) | BHT-101 |
| 種屬 | 人 |
| 生長(zhǎng)特性 | 貼壁細(xì)胞 |
| 細(xì)胞形態(tài) | 上皮細(xì)胞樣 |
| 凍存條件 | 凍存液：55% 基礎(chǔ)培養(yǎng)基+40%FBS+5%DMSO 溫度：液氮 |
| 培養(yǎng)方案A（默認(rèn)） |
培養(yǎng)條件:
氣相：空氣，95%；CO2，5%, 溫度：37℃
|
| 推薦傳代比例 | 1:2-1:6 |
| 推薦換液頻率 | 2-3次/周 |
| 背景描述 | Established from the lymph node metastasis of a 63-year-old woman with anaplastic papillary thyroid carinoma; cells were described in the literature to not produce hormones, but to be partly positive for thyroglobulin- and thyroxine (T4) |
| 年齡（性別） | 女性；63歲 |
| 組織來(lái)源 | 甲狀腺癌 |
| 細(xì)胞類(lèi)型 | 腫瘤細(xì)胞 |
| 腫瘤類(lèi)型 | 甲狀腺癌細(xì)胞 |
| 生物安全等級(jí) | BSL-1 |
| 倍增時(shí)間 | 24 hours (PubMed=8099464); ~2-3 days (DSMZ) |
| 保藏機(jī)構(gòu) | DSMZ; ACC-279 |
STR鑒定
-
STR位點(diǎn)信息
Amelogenin X CSF1PO 12,13 D2S1338 20,23 D3S1358 16,17 D5S818 10,11 D7S820 10,11 D8S1179 13,15 D13S317 12 D16S539 9,11 D18S51 12,15 D19S433 13,14,15 D21S11 29,32.2 FGA 18,24 PentaD 9 PentaE 10,17 TH01 9,9.3 TPOX 8 vWA 19 D6S1043 12,14 D12S391 17,22 D2S441 10,11.3 -
STR鑒定圖
-
參考文獻(xiàn)
-
The EPRS-ATF4-COLI pathway axis is a potential target for anaplastic thyroid carcinoma therapy(2024/04/28)
作者：Li Mi, Jiaye Liu, Yujie Zhang
期刊：PHYTOMEDICINE
DOI：10.1016/j.phymed.2024.155670
影響因子 ：7.900
引用產(chǎn)品：CL-0617
-
RBX1 regulates PKM alternative splicing to facilitate anaplastic thyroid carcinoma metastasis and aerobic glycolysis by destroying the SMAR1/HDAC6 complex(2023/02/21)
作者：Xu Debin, Yu Jichun, Yang Yuting, Du Yunyan, Lu Hongcheng, Zhang Shouhua, Feng Qian, Yu Yi, Hao Liang, Shao Jun, Chen Leifeng
期刊：Cell and Bioscience
DOI：10.1186/s13578-023-00987-8
影響因子 ：7.500
引用產(chǎn)品：CL-0575 CL-0617 CL-0618 CL-0624 CL-0643 CL-0648 CL-0649
-
Pleckstrin homology and RhoGEF domain containing G4 (PLEKHG4) leads to the activation of RhoGTPases promoting the malignant phenotypes of thyroid cancer(2023/06/19)
作者：Qingling Yuan, Yuxia Fan, Zheng Liu
期刊：APOPTOSIS
DOI：10.1007/s10495-023-01861-1
影響因子 ：7.200
-
Anti-Anaplastic Thyroid Cancer (ATC) Effects and Mechanisms of PLX3397 (Pexidartinib), a Multi-Targeted Tyrosine Kinase Inhibitor (TKI)(2022/12/28)
作者：Jingtao Luo, Yun Wang, Lingkun Zhao
期刊：Cancers
影響因子 ：5.200
-
Tripartite motif containing 63, regulated by E26 transformation specific variant 4, facilitates the thyroid carcinoma progression and the AKT, p38, and ERK signaling pathways(2022/04/04)
作者：Jingni He, Ying Zhang, Baiyu Yao
期刊：MOLECULAR AND CELLULAR ENDOCRINOLOGY
影響因子 ：4.100
-
DNMT1/DNMT3a-mediated promoter hypermethylation and transcription activation of ICAM5 augments thyroid carcinoma progression(2024/01/17)
作者：Zanbin Li, Yong Ying, Xiangtai Zeng
期刊：FUNCTIONAL & INTEGRATIVE GENOMICS
DOI：10.1007/s10142-024-01293-3
影響因子 ：2.900
引用產(chǎn)品：CL-0617
-
FOXA2 suppresses PKM2 transcription and affects the Wnt/β-catenin activity to block aerobic glycolysis in thyroid carcinoma(2023/03/22)
作者：Yawei He, Wanjing Chen, Liang Yu
期刊：CLINICAL AND EXPERIMENTAL PHARMACOLOGY AND PHYSIOLOGY
影響因子 ：2.900
FAQs
Q：{{item.question}}
A：{{item.answer}}
產(chǎn)品資料
識(shí)別碼示意圖
娜胡文君.png "邱國(guó)娜/胡文君")
.png "梅文強(qiáng)")
